Cello Health update hits wrong note

0 mins. to read
Cello Health update hits wrong note
Master Investor Magazine

Master Investor Magazine 58Never miss an issue of Master Investor Magazine – sign-up now for free!

Read the latest Master Investor Magazine

AIM-listed healthcare advisory firm Cello Health (LON:CLL) saw its share price fall by 6.31% to 138.20p (as of 13:20 GMT) as it said that the Signal division had been a drag on otherwise strong trading. Management said that the signal arm had performed particularly badly in the fourth quarter but assigned some of this to the impact of the UK general election campaign.

The company said that it would continue to use an acquisitive growth based strategy going forward in to 2019 while looking to split off and dispose of unprofitable business units.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *